Skip to main content
. 2023 Apr 3;2(4):pgad115. doi: 10.1093/pnasnexus/pgad115

Fig. 4.

Fig. 4.

ETC complex I inhibition sensitizes CRPC cells to ADT drugs. A) Incucyte growth analysis (left) or OCR response (right—24 h treatment) of 22Rv1 cells in the presence of increasing concentrations of IACS-010759. B) Incucyte growth analysis of 22Rv1 cells grown in the presence of 10 nM or 20 nM IACS-010759 +/− 10 µM enzalutamide. C).22Rv1 xenograft tumor growth represented as mean tumor volume ± SEM in mice treated with vehicle (n = 7), enzalutamide (25 mg/kg; n = 7), IACS-010759 (7.5 mg/kg; n = 7), or combo (n = 8). Mean tumor volume +/− SD at day 40 post-22Rv1 cell injection (right) in mice treated with IACS-010759 or combo. D) Durability of response of 22Rv1 xenografts in mice treated with vehicle, enzalutamide only, IACS-010759, or combo. Mice were removed from the study when tumor volume surpassed 1800 mm3; data presented as days after 22Rv1 cell injection. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 using Gehan Breslow–Wilcoxon test or two-tailed unpaired t test.